Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?
• MGMT status is linked to the response of RT and temozolomide. • Patients treated with different RT schedules are analyzed according MGMT status. • Methylated MGMT patients could be treated with a reduced RT dose.
Gespeichert in:
| Autor*in: |
Tini, Paolo [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE - Kanuri, Swapna ELSEVIER, 2015, official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:184 ; year:2019 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.clineuro.2019.105445 |
|---|
| Katalog-ID: |
ELV047544112 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV047544112 | ||
| 003 | DE-627 | ||
| 005 | 20230624135608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191021s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clineuro.2019.105445 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000712.pica |
| 035 | |a (DE-627)ELV047544112 | ||
| 035 | |a (ELSEVIER)S0303-8467(19)30241-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 600 |a 690 |q VZ |
| 084 | |a 51.00 |2 bkl | ||
| 084 | |a 51.32 |2 bkl | ||
| 100 | 1 | |a Tini, Paolo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? |
| 264 | 1 | |c 2019 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • MGMT status is linked to the response of RT and temozolomide. • Patients treated with different RT schedules are analyzed according MGMT status. • Methylated MGMT patients could be treated with a reduced RT dose. | ||
| 650 | 7 | |a Dose-survival relationship |2 Elsevier | |
| 650 | 7 | |a MGMT |2 Elsevier | |
| 650 | 7 | |a Glioblastoma |2 Elsevier | |
| 650 | 7 | |a Radiotherapy |2 Elsevier | |
| 650 | 7 | |a Dose reduction |2 Elsevier | |
| 700 | 1 | |a Nardone, Valerio |4 oth | |
| 700 | 1 | |a Pastina, Pierpaolo |4 oth | |
| 700 | 1 | |a Marampon, Francesco |4 oth | |
| 700 | 1 | |a Sebaste, Lucio |4 oth | |
| 700 | 1 | |a Cerase, Alfonso |4 oth | |
| 700 | 1 | |a Tombolini, Vincenzo |4 oth | |
| 700 | 1 | |a Pirtoli, Luigi |4 oth | |
| 700 | 1 | |a Mazzei, Maria Antonietta |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Kanuri, Swapna ELSEVIER |t SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE |d 2015 |d official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology |g Amsterdam [u.a.] |w (DE-627)ELV013090054 |
| 773 | 1 | 8 | |g volume:184 |g year:2019 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.clineuro.2019.105445 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_40 | ||
| 936 | b | k | |a 51.00 |j Werkstoffkunde: Allgemeines |q VZ |
| 936 | b | k | |a 51.32 |j Werkstoffmechanik |q VZ |
| 951 | |a AR | ||
| 952 | |d 184 |j 2019 |h 0 | ||
| author_variant |
p t pt |
|---|---|
| matchkey_str |
tinipaolonardonevaleriopastinapierpaolom:2019----:srdcinfaitodsfailiptetafcebgibatmudronrdohmteaycodntmmpooemt |
| hierarchy_sort_str |
2019 |
| bklnumber |
51.00 51.32 |
| publishDate |
2019 |
| allfields |
10.1016/j.clineuro.2019.105445 doi GBV00000000000712.pica (DE-627)ELV047544112 (ELSEVIER)S0303-8467(19)30241-0 DE-627 ger DE-627 rakwb eng 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Tini, Paolo verfasserin aut Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? 2019 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • MGMT status is linked to the response of RT and temozolomide. • Patients treated with different RT schedules are analyzed according MGMT status. • Methylated MGMT patients could be treated with a reduced RT dose. Dose-survival relationship Elsevier MGMT Elsevier Glioblastoma Elsevier Radiotherapy Elsevier Dose reduction Elsevier Nardone, Valerio oth Pastina, Pierpaolo oth Marampon, Francesco oth Sebaste, Lucio oth Cerase, Alfonso oth Tombolini, Vincenzo oth Pirtoli, Luigi oth Mazzei, Maria Antonietta oth Enthalten in Elsevier Science Kanuri, Swapna ELSEVIER SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE 2015 official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology Amsterdam [u.a.] (DE-627)ELV013090054 volume:184 year:2019 pages:0 https://doi.org/10.1016/j.clineuro.2019.105445 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 184 2019 0 |
| spelling |
10.1016/j.clineuro.2019.105445 doi GBV00000000000712.pica (DE-627)ELV047544112 (ELSEVIER)S0303-8467(19)30241-0 DE-627 ger DE-627 rakwb eng 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Tini, Paolo verfasserin aut Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? 2019 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • MGMT status is linked to the response of RT and temozolomide. • Patients treated with different RT schedules are analyzed according MGMT status. • Methylated MGMT patients could be treated with a reduced RT dose. Dose-survival relationship Elsevier MGMT Elsevier Glioblastoma Elsevier Radiotherapy Elsevier Dose reduction Elsevier Nardone, Valerio oth Pastina, Pierpaolo oth Marampon, Francesco oth Sebaste, Lucio oth Cerase, Alfonso oth Tombolini, Vincenzo oth Pirtoli, Luigi oth Mazzei, Maria Antonietta oth Enthalten in Elsevier Science Kanuri, Swapna ELSEVIER SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE 2015 official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology Amsterdam [u.a.] (DE-627)ELV013090054 volume:184 year:2019 pages:0 https://doi.org/10.1016/j.clineuro.2019.105445 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 184 2019 0 |
| allfields_unstemmed |
10.1016/j.clineuro.2019.105445 doi GBV00000000000712.pica (DE-627)ELV047544112 (ELSEVIER)S0303-8467(19)30241-0 DE-627 ger DE-627 rakwb eng 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Tini, Paolo verfasserin aut Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? 2019 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • MGMT status is linked to the response of RT and temozolomide. • Patients treated with different RT schedules are analyzed according MGMT status. • Methylated MGMT patients could be treated with a reduced RT dose. Dose-survival relationship Elsevier MGMT Elsevier Glioblastoma Elsevier Radiotherapy Elsevier Dose reduction Elsevier Nardone, Valerio oth Pastina, Pierpaolo oth Marampon, Francesco oth Sebaste, Lucio oth Cerase, Alfonso oth Tombolini, Vincenzo oth Pirtoli, Luigi oth Mazzei, Maria Antonietta oth Enthalten in Elsevier Science Kanuri, Swapna ELSEVIER SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE 2015 official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology Amsterdam [u.a.] (DE-627)ELV013090054 volume:184 year:2019 pages:0 https://doi.org/10.1016/j.clineuro.2019.105445 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 184 2019 0 |
| allfieldsGer |
10.1016/j.clineuro.2019.105445 doi GBV00000000000712.pica (DE-627)ELV047544112 (ELSEVIER)S0303-8467(19)30241-0 DE-627 ger DE-627 rakwb eng 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Tini, Paolo verfasserin aut Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? 2019 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • MGMT status is linked to the response of RT and temozolomide. • Patients treated with different RT schedules are analyzed according MGMT status. • Methylated MGMT patients could be treated with a reduced RT dose. Dose-survival relationship Elsevier MGMT Elsevier Glioblastoma Elsevier Radiotherapy Elsevier Dose reduction Elsevier Nardone, Valerio oth Pastina, Pierpaolo oth Marampon, Francesco oth Sebaste, Lucio oth Cerase, Alfonso oth Tombolini, Vincenzo oth Pirtoli, Luigi oth Mazzei, Maria Antonietta oth Enthalten in Elsevier Science Kanuri, Swapna ELSEVIER SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE 2015 official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology Amsterdam [u.a.] (DE-627)ELV013090054 volume:184 year:2019 pages:0 https://doi.org/10.1016/j.clineuro.2019.105445 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 184 2019 0 |
| allfieldsSound |
10.1016/j.clineuro.2019.105445 doi GBV00000000000712.pica (DE-627)ELV047544112 (ELSEVIER)S0303-8467(19)30241-0 DE-627 ger DE-627 rakwb eng 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Tini, Paolo verfasserin aut Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? 2019 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • MGMT status is linked to the response of RT and temozolomide. • Patients treated with different RT schedules are analyzed according MGMT status. • Methylated MGMT patients could be treated with a reduced RT dose. Dose-survival relationship Elsevier MGMT Elsevier Glioblastoma Elsevier Radiotherapy Elsevier Dose reduction Elsevier Nardone, Valerio oth Pastina, Pierpaolo oth Marampon, Francesco oth Sebaste, Lucio oth Cerase, Alfonso oth Tombolini, Vincenzo oth Pirtoli, Luigi oth Mazzei, Maria Antonietta oth Enthalten in Elsevier Science Kanuri, Swapna ELSEVIER SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE 2015 official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology Amsterdam [u.a.] (DE-627)ELV013090054 volume:184 year:2019 pages:0 https://doi.org/10.1016/j.clineuro.2019.105445 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 184 2019 0 |
| language |
English |
| source |
Enthalten in SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE Amsterdam [u.a.] volume:184 year:2019 pages:0 |
| sourceStr |
Enthalten in SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE Amsterdam [u.a.] volume:184 year:2019 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Werkstoffkunde: Allgemeines Werkstoffmechanik |
| institution |
findex.gbv.de |
| topic_facet |
Dose-survival relationship MGMT Glioblastoma Radiotherapy Dose reduction |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE |
| authorswithroles_txt_mv |
Tini, Paolo @@aut@@ Nardone, Valerio @@oth@@ Pastina, Pierpaolo @@oth@@ Marampon, Francesco @@oth@@ Sebaste, Lucio @@oth@@ Cerase, Alfonso @@oth@@ Tombolini, Vincenzo @@oth@@ Pirtoli, Luigi @@oth@@ Mazzei, Maria Antonietta @@oth@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV013090054 |
| dewey-sort |
3610 |
| id |
ELV047544112 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047544112</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624135608.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.clineuro.2019.105445</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000712.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047544112</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0303-8467(19)30241-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tini, Paolo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• MGMT status is linked to the response of RT and temozolomide. • Patients treated with different RT schedules are analyzed according MGMT status. • Methylated MGMT patients could be treated with a reduced RT dose.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dose-survival relationship</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MGMT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glioblastoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dose reduction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nardone, Valerio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pastina, Pierpaolo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marampon, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sebaste, Lucio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cerase, Alfonso</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tombolini, Vincenzo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pirtoli, Luigi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mazzei, Maria Antonietta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Kanuri, Swapna ELSEVIER</subfield><subfield code="t">SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE</subfield><subfield code="d">2015</subfield><subfield code="d">official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV013090054</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:184</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.clineuro.2019.105445</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">184</subfield><subfield code="j">2019</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Tini, Paolo |
| spellingShingle |
Tini, Paolo ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier Dose-survival relationship Elsevier MGMT Elsevier Glioblastoma Elsevier Radiotherapy Elsevier Dose reduction Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? |
| authorStr |
Tini, Paolo |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV013090054 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 600 - Technology 690 - Buildings |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? Dose-survival relationship Elsevier MGMT Elsevier Glioblastoma Elsevier Radiotherapy Elsevier Dose reduction Elsevier |
| topic |
ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier Dose-survival relationship Elsevier MGMT Elsevier Glioblastoma Elsevier Radiotherapy Elsevier Dose reduction |
| topic_unstemmed |
ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier Dose-survival relationship Elsevier MGMT Elsevier Glioblastoma Elsevier Radiotherapy Elsevier Dose reduction |
| topic_browse |
ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier Dose-survival relationship Elsevier MGMT Elsevier Glioblastoma Elsevier Radiotherapy Elsevier Dose reduction |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
v n vn p p pp f m fm l s ls a c ac v t vt l p lp m a m ma mam |
| hierarchy_parent_title |
SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE |
| hierarchy_parent_id |
ELV013090054 |
| dewey-tens |
610 - Medicine & health 600 - Technology 690 - Building & construction |
| hierarchy_top_title |
SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV013090054 |
| title |
Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? |
| ctrlnum |
(DE-627)ELV047544112 (ELSEVIER)S0303-8467(19)30241-0 |
| title_full |
Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? |
| author_sort |
Tini, Paolo |
| journal |
SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE |
| journalStr |
SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Tini, Paolo |
| container_volume |
184 |
| class |
610 VZ 600 690 VZ 51.00 bkl 51.32 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Tini, Paolo |
| doi_str_mv |
10.1016/j.clineuro.2019.105445 |
| dewey-full |
610 600 690 |
| title_sort |
is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to mgmt promoter methylation status without jeopardizing survival? |
| title_auth |
Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? |
| abstract |
• MGMT status is linked to the response of RT and temozolomide. • Patients treated with different RT schedules are analyzed according MGMT status. • Methylated MGMT patients could be treated with a reduced RT dose. |
| abstractGer |
• MGMT status is linked to the response of RT and temozolomide. • Patients treated with different RT schedules are analyzed according MGMT status. • Methylated MGMT patients could be treated with a reduced RT dose. |
| abstract_unstemmed |
• MGMT status is linked to the response of RT and temozolomide. • Patients treated with different RT schedules are analyzed according MGMT status. • Methylated MGMT patients could be treated with a reduced RT dose. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 |
| title_short |
Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? |
| url |
https://doi.org/10.1016/j.clineuro.2019.105445 |
| remote_bool |
true |
| author2 |
Nardone, Valerio Pastina, Pierpaolo Marampon, Francesco Sebaste, Lucio Cerase, Alfonso Tombolini, Vincenzo Pirtoli, Luigi Mazzei, Maria Antonietta |
| author2Str |
Nardone, Valerio Pastina, Pierpaolo Marampon, Francesco Sebaste, Lucio Cerase, Alfonso Tombolini, Vincenzo Pirtoli, Luigi Mazzei, Maria Antonietta |
| ppnlink |
ELV013090054 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.clineuro.2019.105445 |
| up_date |
2024-07-06T23:10:37.669Z |
| _version_ |
1803873091762257920 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047544112</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624135608.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.clineuro.2019.105445</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000712.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047544112</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0303-8467(19)30241-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tini, Paolo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• MGMT status is linked to the response of RT and temozolomide. • Patients treated with different RT schedules are analyzed according MGMT status. • Methylated MGMT patients could be treated with a reduced RT dose.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dose-survival relationship</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MGMT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glioblastoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dose reduction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nardone, Valerio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pastina, Pierpaolo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marampon, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sebaste, Lucio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cerase, Alfonso</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tombolini, Vincenzo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pirtoli, Luigi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mazzei, Maria Antonietta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Kanuri, Swapna ELSEVIER</subfield><subfield code="t">SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE</subfield><subfield code="d">2015</subfield><subfield code="d">official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV013090054</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:184</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.clineuro.2019.105445</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">184</subfield><subfield code="j">2019</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.4020147 |